Health Care·Biotechnology·$11.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-3.18 | N/A | -31.46% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-3.18 | N/A | -31.46% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the impact of external factors on performance. They reiterated their commitment to advancing their pipeline.
Management highlighted ongoing challenges in the current market environment.
They emphasized the importance of continued research and development efforts.
Madrigal Pharmaceuticals reported a larger-than-expected loss per share, leading to a 3.12% decline in stock price. The lack of revenue figures and guidance adds uncertainty for investors. Management's cautious tone suggests challenges ahead as they navigate the current market landscape.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MARATHON PETE CORP
Aug 3, 2020